181 related articles for article (PubMed ID: 8581459)
1. The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).
Jonkman-De Vries JD; Rosing H; Henrar RE; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 1995; 49(6):283-8. PubMed ID: 8581459
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).
Jonkman-de Vries JD; de Graaff-Teulen MJ; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Invest New Drugs; 1994; 12(4):303-14. PubMed ID: 7775131
[TBL] [Abstract][Full Text] [Related]
3. Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244).
Vries JD; Doppenberg WG; Henrar RE; Bult A; Beijnen JH
J Pharm Sci; 1996 Nov; 85(11):1227-33. PubMed ID: 8923330
[TBL] [Abstract][Full Text] [Related]
4. Comments on 'Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244)'.
Bergon M
J Pharm Sci; 1997 Sep; 86(9):1070-1. PubMed ID: 9294825
[No Abstract] [Full Text] [Related]
5. Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product.
Nassar MN; Nesarikar VN; Lozano R; Parker WL; Huang Y; Palaniswamy V; Xu W; Khaselev N
Pharm Dev Technol; 2004; 9(2):189-95. PubMed ID: 15202578
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
7. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.
Li Y; Hewitt D; Lentz YK; Ji JA; Zhang TY; Zhang K
Anal Chem; 2014 May; 86(10):5150-7. PubMed ID: 24749737
[TBL] [Abstract][Full Text] [Related]
8. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
van Tellingen O; Punt CJ; Awada A; Wagener DJ; Piccart MJ; Groot Y; Schaaf LJ; Henrar RE; Nooijen WJ; Beijnen JH
Cancer Chemother Pharmacol; 1998; 41(5):377-84. PubMed ID: 9523733
[TBL] [Abstract][Full Text] [Related]
9. A novel aqueous parenteral formulation of docetaxel using prodrugs.
Park MH; Keum CG; Song JY; Kim D; Cho CW
Int J Pharm; 2014 Feb; 462(1-2):1-7. PubMed ID: 24370840
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of hydroperoxides in common pharmaceutical excipients.
Wasylaschuk WR; Harmon PA; Wagner G; Harman AB; Templeton AC; Xu H; Reed RA
J Pharm Sci; 2007 Jan; 96(1):106-16. PubMed ID: 16917844
[TBL] [Abstract][Full Text] [Related]
11. [Study on selecting the suitable solubilizing excipients for Shengmai injection].
Zhang SF; Yan D; Tang HY; Li HB; Wang YS; Xiao XH; Yang M
Zhong Yao Cai; 2009 Jun; 32(6):969-72. PubMed ID: 19764337
[TBL] [Abstract][Full Text] [Related]
12. Use of high resolution mass spectrometry for analysis of polymeric excipients in drug delivery formulations.
Perez Hurtado P; Lam PY; Kilgour D; Bristow A; McBride E; O'Connor PB
Anal Chem; 2012 Oct; 84(20):8579-86. PubMed ID: 23003319
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of the esterification of active pharmaceutical ingredients containing carboxylic acid functionality in polyethylene glycol: formulation implications.
Schou-Pedersen AM; Hansen SH; Moesgaard B; Østergaard J
J Pharm Sci; 2014 Aug; 103(8):2424-33. PubMed ID: 24961667
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
[TBL] [Abstract][Full Text] [Related]
15. On-line coupling of hydrophobic interaction column with reverse phase column -charged aerosol detector/mass spectrometer to characterize polysorbates in therapeutic protein formulations.
He Y; Brown P; Bailey Piatchek MR; Carroll JA; Jones MT
J Chromatogr A; 2019 Feb; 1586():72-81. PubMed ID: 30551943
[TBL] [Abstract][Full Text] [Related]
16. Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers.
Traini D; Young PM; Rogueda P; Price R
Int J Pharm; 2006 Aug; 320(1-2):58-63. PubMed ID: 16735100
[TBL] [Abstract][Full Text] [Related]
17. Creating Drug Solubilization Compartments via Phase Separation in Multicomponent Buccal Patches Prepared by Direct Hot Melt Extrusion-Injection Molding.
Alhijjaj M; Bouman J; Wellner N; Belton P; Qi S
Mol Pharm; 2015 Dec; 12(12):4349-62. PubMed ID: 26551593
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
van Tellingen O; Nooijen WJ; Schaaf LJ; van der Valk M; van Asperen J; Henrar RE; Beijnen JH
Cancer Res; 1998 Jun; 58(11):2410-6. PubMed ID: 9622082
[TBL] [Abstract][Full Text] [Related]
19. Effects of polysorbate 80 on the in-vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats.
Tønsberg H; Holm R; Bisgaard J; Jacobsen J; Müllertz A
J Pharm Pharmacol; 2010 Jan; 62(1):63-70. PubMed ID: 20723000
[TBL] [Abstract][Full Text] [Related]
20. Study of phase behavior of poly(ethylene glycol)-polysorbate 80 and poly(ethylene glycol)-polysorbate 80-water mixtures.
Tejwani RW; Joshi HN; Varia SA; Serajuddin AT
J Pharm Sci; 2000 Jul; 89(7):946-50. PubMed ID: 10861596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
